Iseganan is under investigation in clinical trial NCT00022373 (Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer). ISEGANAN is a Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications. The directory classifies it as a discontinued API with a peptide source/manufacturing origin. Other names for this substance include IB-367, Q9SAI36COS and DTXSID80180415. Its PubChem CID is 16131103.
Iseganan
| CAS No | 257277-05-7 |
|---|---|
| Molecular Formula | C78H126N30O18S4 |
| Molecular Weight | 1900.3 g/mol |
| Synonyms | (1R,4S,7R,12R,15S,18R,21S,24S,30S)-N-[(2S)-1-[[2-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]-7-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-5-carbamimidamidopentanoyl]amino]acetyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-21-benzyl-24,30-bis(3-carbamimidamidopropyl)-4-[(4-hydroxyphenyl)methyl]-3,6,14,17,20,23,26,29,32-nonaoxo-15-propan-2-yl-9,10,34,35-tetrathia-2,5,13,16,19,22,25,28,31-nonazabicyclo[16.14.4]hexatriacontane-12-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Iseganan is under investigation in clinical trial NCT00022373 (Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer).
The listed CAS number is 257277-05-7.
The listed molecular formula is C78H126N30O18S4.
The listed molecular weight is 1900.3 g/mol.
The source lists IB-367, Q9SAI36COS and DTXSID80180415.
It is listed as a discontinued API with a peptide origin.